Fabry Disease - literature review
DOI:
https://doi.org/10.12775/JEHS.2024.71.56177Keywords
Fabry disease, Alpha-galactosidase A, GLA, lyso-Gb3Abstract
Introduction and objective: Fabry disease (FD) is a rare lysosomal storage disorder that can manifest in classical and atypical forms, with the latter being more common. It results from deficient alpha-galactosidase activity, leading to the accumulation of globotriaosylceramide (Gb3), causing inflammation, cellular damage, and mitochondrial dysfunction. The aim of this publication is to discuss various aspects of Fabry disease based on the latest literature.
Review Methods: The PubMed database was searched for scientific articles where the terms "Fabry disease" or "FD" appear in the title, abstract, or keywords. The focus was on articles published between 2017 and 2024, although in some cases, older sources were consulted when more recent data was lacking.
Brief Description of the State of Knowledge: The Fabry disease occurs with a frequency between 1:40,000 and 1:117,000 live male births. Symptoms include proteinuria, kidney failure, hypertrophic cardiomyopathy, valve defects, peripheral neuropathy, and gastrointestinal issues. The disease affects life expectancy, primarily due to cardiovascular complications. Early diagnosis is often delayed due to non-specific symptoms, and prognosis tends to be worse in males. Current treatments include enzyme replacement therapy (ERT), chaperone therapy with migalastat, and second-generation ERT.
Summary: Given the rarity of Fabry disease, research is limited, and there is a need for more studies to explore novel therapeutic options that could improve patient quality of life and mitigate the disease's complications.
References
Lerario S, Monti L, Ambrosetti I, et al. Fabry disease: a rare disorder calling for personalized medicine. Int Urol Nephrol. 2024 Oct;56(10):3161-3172. doi: 10.1007/s11255-024-04042-4.
Bokhari SRA, Zulfiqar H, Hariz A. Fabry Disease. [Updated 2023 Jul 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK435996/
Mignani R, Pieruzzi F, Berri F, et al. FAbry STabilization indEX (FASTEX): an innovative tool for the assessment of clinical stabilization in Fabry disease. Clin Kidney J. 2016 Oct;9(5):739-47. doi: 10.1093/ckj/sfw082.
Sens F, Guittard L, Knebelmann B, et al. Prevalence of Fabry Disease in Patients on Dialysis in France. Int J Mol Sci. 2024 Sep 20;25(18):10104. doi: 10.3390/ijms251810104.
Veldman BCF, Schoenmakers DH, van Dussen L, et al. Establishing Treatment Effectiveness in Fabry Disease: Observation-Based Recommendations for Improvement. Int J Mol Sci. 2024 Sep 9;25(17):9752. doi: 10.3390/ijms25179752.
Viggiano E, Politano L. X Chromosome Inactivation in Carriers of Fabry Disease: Review and Meta-Analysis. Int J Mol Sci. 2021 Jul 17;22(14):7663. doi: 10.3390/ijms22147663.
Ortiz A, Germain DP, Desnick RJ, et al. Fabry disease revisited: Management and treatment recommendations for adult patients. Mol Genet Metab. 2018 Apr;123(4):416-427. doi: 10.1016/j.ymgme.2018.02.014.
Pieroni M, Moon JC, Arbustini E, et al. Cardiac Involvement in Fabry Disease: JACC Review Topic of the Week. J Am Coll Cardiol. 2021 Feb 23;77(7):922-936. doi: 10.1016/j.jacc.2020.12.024.
Ivanova M. Altered Sphingolipids Metabolism Damaged Mitochondrial Functions: Lessons Learned From Gaucher and Fabry Diseases. J Clin Med. 2020 Apr 14;9(4):1116. doi: 10.3390/jcm9041116.
Ravarotto V, Carraro G, Pagnin E, et al. Oxidative stress and the altered reaction to it in Fabry disease: A possible target for cardiovascular-renal remodeling? PLoS One. 2018 Sep 27;13(9):e0204618. doi: 10.1371/journal.pone.0204618.
Arends M, Wanner C, Hughes D, et al. Characterization of Classical and Nonclassical Fabry Disease: A Multicenter Study. J Am Soc Nephrol. 2017 May;28(5):1631-1641. doi: 10.1681/ASN.2016090964
Gragnaniello V, Burlina AP, Polo G, et al. Newborn Screening for Fabry Disease in Northeastern Italy: Results of Five Years of Experience. Biomolecules. 2021 Jun 27;11(7):951. doi: 10.3390/biom11070951.
Gilchrist M, Casanova F, Tyrrell JS, et al. Prevalence of Fabry disease-causing variants in the UK Biobank. J Med Genet. 2023 Apr;60(4):391-396. doi: 10.1136/jmg-2022-108523. Epub 2022 Aug 17.
Moiseev S, Tao E, Moiseev A, et al. The Benefits of Family Screening in Rare Diseases: Genetic Testing Reveals 165 New Cases of Fabry Disease among At-Risk Family Members of 83 Index Patients. Genes (Basel). 2022 Sep 9;13(9):1619. doi: 10.3390/genes13091619.
Sodré LSS, Huaira RMNH, Bastos MG, et al. Screening for Fabry Disease in Kidney Disease: a Cross-Sectional Study in Males and Females. Kidney Blood Press Res. 2017;42(6):1258-1265. doi: 10.1159/000485929.
Moiseev S, Fomin V, Savostyanov K, et al. The Prevalence and Clinical Features of Fabry Disease in Hemodialysis Patients: Russian Nationwide Fabry Dialysis Screening Program. Nephron. 2019;141(4):249-255. doi: 10.1159/000495886.
Cho E, Park JT, Yoo TH, et al. Frequency of Fabry disease in chronic kidney disease patients including patients on renal replacement therapy in Korea. Kidney Res Clin Pract. 2024 Jan;43(1):71-81. doi: 10.23876/j.krcp.22.087.
Doheny D, Srinivasan R, Pagant S, et al. Fabry Disease: prevalence of affected males and heterozygotes with pathogenic GLA mutations identified by screening renal, cardiac and stroke clinics, 1995-2017. J Med Genet. 2018 Apr;55(4):261-268. doi: 10.1136/jmedgenet-2017-105080.
Germain DP, Altarescu G, Barriales-Villa R, et al. An expert consensus on practical clinical recommendations and guidance for patients with classic Fabry disease. Mol Genet Metab. 2022 Sep-Oct;137(1-2):49-61. doi: 10.1016/j.ymgme.2022.07.010.
Skrunes R, Tøndel C, Leh S, et al. Long-Term Dose-Dependent Agalsidase Effects on Kidney Histology in Fabry Disease. Clin J Am Soc Nephrol. 2017 Sep 7;12(9):1470-1479. doi: 10.2215/CJN.01820217.
Tøndel C, Kanai T, Larsen KK, et al. Foot process effacement is an early marker of nephropathy in young classic Fabry patients without albuminuria. Nephron. 2015;129(1):16-21. doi: 10.1159/000369309.
Feriozzi S, Rozenfeld P. Pathology and pathogenic pathways in fabry nephropathy. Clin Exp Nephrol. 2021 Sep;25(9):925-934. doi: 10.1007/s10157-021-02058-z.
Andreucci M, Provenzano M, Faga T, et al. Aortic Aneurysms, Chronic Kidney Disease and Metalloproteinases. Biomolecules. 2021 Jan 30;11(2):194. doi: 10.3390/biom11020194.
Cortés-Saladelafont E, Fernández-Martín J, Ortolano S. Fabry Disease and Central Nervous System Involvement: From Big to Small, from Brain to Synapse. Int J Mol Sci. 2023 Mar 9;24(6):5246. doi: 10.3390/ijms24065246.
Azevedo O, Cordeiro F, Gago MF, et al. Fabry Disease and the Heart: A Comprehensive Review. Int J Mol Sci. 2021 Apr 23;22(9):4434. doi: 10.3390/ijms22094434.
Tuttolomondo A, Baglio I, Riolo R, et al. Molecular Pathogenesis of Central and Peripheral Nervous System Complications in Anderson-Fabry Disease. Int J Mol Sci. 2023 Dec 20;25(1):61. doi: 10.3390/ijms25010061.
Gambini G, Scartozzi L, Giannuzzi F, et al. Ophthalmic Manifestations in Fabry Disease: Updated Review. J Pers Med. 2023 May 27;13(6):904. doi: 10.3390/jpm13060904.
Beck M, Ramaswami U, Hernberg-Ståhl E, et al. Twenty years of the Fabry Outcome Survey (FOS): insights, achievements, and lessons learned from a global patient registry. Orphanet J Rare Dis. 2022 Jun 20;17(1):238. doi: 10.1186/s13023-022-02392-9.
Svensson CK, Feldt-Rasmussen U, Backer V. Fabry disease, respiratory symptoms, and airway limitation - a systematic review. Eur Clin Respir J. 2015 Jun 26;2. doi: 10.3402/ecrj.v2.26721.
Bolsover FE, Murphy E, Cipolotti L, et al. Cognitive dysfunction and depression in Fabry disease: a systematic review. J Inherit Metab Dis. 2014 Mar;37(2):177-87. doi: 10.1007/s10545-013-9643-x.
Wang WT, Sung SH, Liao JN, et al. Cardiac manifestations in patients with classical or cardiac subtype of Fabry disease. J Chin Med Assoc. 2020 Sep;83(9):825-829. doi: 10.1097/JCMA.0000000000000379.
Kramer J, Weidemann F. Biomarkers for Diagnosing and Staging of Fabry Disease. Curr Med Chem. 2018;25(13):1530-1537. doi: 10.2174/0929867324666170616102112.
Baig S, Vijapurapu R, Alharbi F, et al. Diagnosis and treatment of the cardiovascular consequences of Fabry disease. QJM. 2019 Jan 1;112(1):3-9. doi: 10.1093/qjmed/hcy120.
Burlina AB, Polo G, Salviati L, et al. Newborn screening for lysosomal storage disorders by tandem mass spectrometry in North East Italy. J Inherit Metab Dis. 2018 Mar;41(2):209-219. doi: 10.1007/s10545-017-0098-3.
Macklin S, Laney D, Lisi E, et al. The Psychosocial Impact of Carrying a Debated Variant in the GLA Gene. J Genet Couns. 2018 Feb;27(1):217-224. doi: 10.1007/s10897-017-0139-y.
Echevarria L, Benistan K, Toussaint A, et al. X-chromosome inactivation in female patients with Fabry disease. Clin Genet. 2016 Jan;89(1):44-54. doi: 10.1111/cge.12613.
Rossanti R, Nozu K, Fukunaga A, et al. X-chromosome inactivation patterns in females with Fabry disease examined by both ultra-deep RNA sequencing and methylation-dependent assay. Clin Exp Nephrol. 2021 Nov;25(11):1224-1230. doi: 10.1007/s10157-021-02099-4. Epub
Viggiano E, Madej-Pilarczyk A, Carboni N,et al. X-Linked Emery-Dreifuss Muscular Dystrophy: Study Of X-Chromosome Inactivation and Its Relation with Clinical Phenotypes in Female Carriers. Genes (Basel). 2019 Nov 11;10(11):919. doi: 10.3390/genes10110919.
Ponleitner M, Gatterer C, Bsteh G, et al. Investigation of serum neurofilament light chain as a biomarker in Fabry disease. Sci Rep. 2024 Oct 3;14(1):23033. doi: 10.1038/s41598-024-73537-y.
Solomon M, Muro S. Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives. Adv Drug Deliv Rev. 2017 Sep 1;118:109-134. doi: 10.1016/j.addr.2017.05.004. Epub 2017 May 11.
Azevedo O, Gago MF, Miltenberger-Miltenyi G, et al. Fabry Disease Therapy: State-of-the-Art and Current Challenges. Int J Mol Sci. 2020 Dec 28;22(1):206. doi: 10.3390/ijms22010206.
Lenders M, Brand E. Effects of Enzyme Replacement Therapy and Antidrug Antibodies in Patients with Fabry Disease. J Am Soc Nephrol. 2018 Sep;29(9):2265-2278. doi: 10.1681/ASN.2018030329.
van der Veen SJ, van Kuilenburg ABP, Hollak CEM, et al. Antibodies against recombinant alpha-galactosidase A in Fabry disease: Subclass analysis and impact on response to treatment. Mol Genet Metab. 2019 Feb;126(2):162-168. doi: 10.1016/j.ymgme.2018.11.008.
Lenders M, Brand E. Assessment and impact of dose escalation on anti-drug antibodies in Fabry disease. Front Immunol. 2022 Dec 9;13:1024963. doi: 10.3389/fimmu.2022.1024963.
Lenders M, Oder D, Nowak A, et al. Impact of immunosuppressive therapy on therapy-neutralizing antibodies in transplanted patients with Fabry disease. J Intern Med. 2017 Sep;282(3):241-253. doi: 10.1111/joim.12647.
Feldt-Rasmussen U, Hughes D, Sunder-Plassmann G, et al. Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study. Mol Genet Metab. 2020 Sep-Oct;131(1-2):219-228. doi: 10.1016/j.ymgme.2020.07.007.
Schiffmann R, Goker-Alpan O, Holida M, et al. Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1-year Phase 1/2 clinical trial. J Inherit Metab Dis. 2019 May;42(3):534-544. doi: 10.1002/jimd.12080.
X. Provenzano M, Rivoli L, Garofalo C, et al. Renal resistive index in chronic kidney disease patients: Possible determinants and risk profile. PLoS One. 2020 Apr 1;15(4):e0230020. doi: 10.1371/journal.pone.0230020.
Svarstad E, Marti HP. The Changing Landscape of Fabry Disease. Clin J Am Soc Nephrol. 2020 Apr 7;15(4):569-576. doi: 10.2215/CJN.09480819.
Warnock DG, Thomas CP, Vujkovac B, et al. Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy. J Med Genet. 2015 Dec;52(12):860-6. doi: 10.1136/jmedgenet-2015-103471.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Krystian Wdowiak, Agnieszka Maciocha, Julia Wąż, Aleksandra Witas, Adrian Muzyka, Julia Rydzek, Ewa Gardocka
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 111
Number of citations: 0
